Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eicosapentaenoic acid monoglyceride
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eicosapentaenoic acid monoglyceride is a chemical derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA), where EPA is present as a monoglyceride rather than a free fatty acid or ethyl ester. Monoglyceride forms are used to potentially increase the bioavailability of EPA compared to traditional forms such as triglycerides or ethyl esters. EPA itself is a long-chain polyunsaturated fatty acid primarily known for cardiovascular benefits, anti-inflammatory effects, and possible cognitive and psychiatric effects. The mechanism of action for its lipid-lowering effect involves reduction of hepatic triglyceride synthesis, increased β-oxidation, inhibition of diacylglycerol acyltransferase in the liver, and increased lipoprotein lipase activity, resulting in decreased plasma triglyceride levels[2][3][4]. Eicosapentaenoic acid monoglyceride is marketed as a dietary supplement, not as a pharmaceutical drug.
- Brand names
- MAG-O3MAG-O-3MAG-O 3
- Other names
- EPMmonoglyceride form of eicosapentaenoic acid
02
Targets
MLXIPL (ChREBP / MLXIPL)PPARG (Peroxisome proliferator-activated receptor gamma)DGAT1 (Diacylglycerol O-acyltransferase 1)CIDEA (Cell death-inducing DFFA-like effector A)SCD1 (Stearoyl-CoA desaturase 1)LPL (Lipoprotein lipase)SREBP-1 / SREBF1 (SREBP-1)
Beyond the preview
Go deeper on eicosapentaenoic acid monoglyceride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eicosapentaenoic acid monoglyceride.